This website is available in:
To change websites, find a country in the A - Z list then choose a language.
To change websites, click on the map pins to find a country then choose a language.
HomeLife SciencesBiopharmaceutical ServicesClinical Research ServicesClinical PharmacologyRegulatory Phase I Clinical Trials
Our clinical Phase I Unit provides clients with a full range of clinical research services compliant with EMEA and FDA requirements to facilitate your “go/no go” decisions during clinical development. We offer a large range of Phase I studies including drug interaction (DDI), TQT/QTc, as well as BA/BE and ADME/pharmacokinetic studies.
SGS performs five to six TQT/QTc studies per year with an average of 24,000 ECGs per trial. We offer:
With partners specializing in cardiac data reading (ECG/Holter), we have developed a strong expertise in providing high-quality ECG reading and analysis in QT prolongation and safety pharmacology studies to the pharmaceutical and biotech industries.
Drug-Drug Interaction (DDI), Bioavailability/Bioequivalence (BA/BE), ADME/Pharmacokinetic Services:
Contact SGS today to learn how we can help with your early Phase I clinical trials.